Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Louisiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Louisiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Louisiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Lavie (NPI 1023374659)

Field	Value
Entity Type	Individual
Organization	Daniel Lavie
Address	4950 Essen Ln Ste 500
City	Baton Rouge
State	LA
ZIP	70809
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 9, 2012

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider is effectively single-payer: lifetime Medicare revenue is $1.1M and there is no Medicaid billing on file, so all observed claims activity and revenue are concentrated in the Medicare program. Analysts should treat Medicaid market dynamics as irrelevant for this individual when modeling payer mix or access to low-income populations.

Revenue concentration is high and dominated by a handful of drugs: the top 3 Medicare codes by revenue account for 76.1% of the provider's total Medicare revenue, driven primarily by J9299 (59.8% of Medicare revenue) plus J1449 and one high-level E/M code. This indicates the practice’s Medicare income depends heavily on a small set of therapeutic products and a high-intensity office visit code.

Clinical and service-line profile: the code mix (large volumes of J9299 nivolumab injections, J1449 eflapegrastim, and chemotherapy administration codes such as 96413 and 96417) is consistent with an outpatient hematology/oncology infusion practice that provides immunotherapy and supportive oncology drugs alongside E/M visits. The presence of high-volume drug administration codes suggests the practice operates a treatment/infusion setting rather than solely consultative care.

Competitive standing on J9299: the provider’s J9299 activity ($665.7K, 28.9K claims) ranks #85 of 505 nationally (83th percentile), which places the provider in a typical, unremarkable national volume band for nivolumab rather than as a top national aggregator. Despite the large share of this provider’s revenue coming from J9299, the rank suggests many peers deliver similar or greater volumes.

E/M utilization is unusually high for office visit intensity: 99215 accounts for $82K (7.4% of Medicare revenue) and ranks #1055 of 145531 providers nationally (99th percentile) and 99214 also ranks notably high at the 96th percentile. These descriptors (extreme outlier for 99215; notably above typical for 99214) indicate the provider bills a substantially higher-than-typical volume of high-complexity outpatient E/M visits compared with national peers, consistent with ongoing management of complex oncology patients.

Specialty-supportive drugs and infusion add-ons show typical participation: codes such as J2506 (pegfilgrastim) and 96413 (chemotherapy infusion) fall in percentiles described as typical or unremarkable (82th and 86th percentiles respectively), indicating the provider’s use of supportive growth factors and chemotherapy administration is within normal bounds for oncology peers rather than an outlier. These codes together diversify revenue beyond the dominant immunotherapy line item.

Tenure and experience: the NPI was enumerated on 2012-04-09 (~14 years ago), indicating over a decade in Medicare billing which supports interpreting current patterns as established practice behavior rather than early-career volatility. This longevity, combined with concentrated drug revenue, suggests a stable oncology infusion operation.

Operational implication for payers and network managers: given the concentration of Medicare revenue in high-cost injectable oncology drugs and high-complexity E/M visits, payers should expect this provider to be materially important for outpatient oncology drug delivery in Baton Rouge but not a national leader on nivolumab. Contracting or utilization management efforts should focus on drug acquisition, infusion capacity, and high-intensity visit utilization patterns rather than primary-care or Medicaid-oriented services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

36 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	28,940	$20	$665.7K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	3,830	$30	$99.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	630	$130	$82K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	800	$90	$70.6K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	680	$90	$62.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	420	$90	$38.2K
J1439	Injection, ferric carboxymaltose, 1 mg	23,250	$1	$23.3K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	50	$160	$8.5K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	180	$50	$8.3K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	80	$90	$6.9K

Showing 1–10 of 36

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 36 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Louisiana Distribution

Daniel Lavie — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Louisiana

Full comparison — all codes billed, vs. state median

36 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9299	2	10	39,670	$20	$929.9K
J1449	1	10	3,830	$30	$98.6K
J3490	8	20	50	$620	$49.1K
J2506	1	10	400	$80	$38.2K
96413	11	70	140	$90	$22.8K
J1439	6	10	23,630	$1	$20.1K
99214	291	6,670	110	$80	$16.5K
99232	1,478	2,580	90	$60	$13.3K
99233	924	2,010	70	$90	$12.3K
99215	13	1,650	40	$110	$8.4K

Showing 1–10 of 36

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Lavie, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mary Bird Perkins Cancer Center	LA	Clinical Medical Laboratory	$64.4K	$8.4M
Jack Saux	LA	Hematology & Oncology Physician	$2.8M	$0
Barry Charnick	FL	Nuclear Radiology Physician	$1.3M	$0
Bryan Bienvenu	LA	Hematology & Oncology Physician	$964.2K	$0
Manish Dhawan	LA	Hematology & Oncology Physician	$870.9K	$24.3K
Jingya Wang	LA	Radiation Oncology Physician	$856.4K	$0
Andrew Elson	LA	Radiation Oncology Physician	$825.1K	$0
Gregory Henkelmann	LA	Radiation Oncology Physician	$754.9K	$0
Konstantin Kovtun	LA	Radiation Oncology Physician	$709K	$0
Jose Rodriguez	FL	Diagnostic Radiology Physician	$659.4K	$0

Nearby Providers

Other providers in the same ZIP code as Daniel Lavie, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Prescribed Pediatric Extended Care, Inc	LA	Medically Fragile Infants and Children Day Care	$0	$40.3M
Cognitive Development Center Of Baton Rouge	LA	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$29M
Baton Rouge General Medical Center	LA	General Acute Care Hospital	$0	$24.3M
Serenity Treatment Center Of Louisiana LLC	LA	Substance Abuse Rehabilitation Facility	$0	$22.4M
Special Needs Unlimited, L.L.C.	LA	Developmental Disabilities Clinic/Center	$0	$22.4M
Caregiver Homes Of Louisiana, Inc	LA	Case Management Agency	$0	$15.9M
Baton Rouge Treatment Center, LLC	LA	Methadone Clinic	$139.4K	$13.5M
Leading Health Care Of La, Inc.	LA	In Home Supportive Care Agency	$0	$12.8M
Alliance Care LLC	LA	In Home Supportive Care Agency	$0	$12.3M
Hometown Senior Care LLC	LA	In Home Supportive Care Agency	$0	$11M

Daniel Lavie — Billing Profile & Reimbursement Data

Sign up for Daniel Lavie — Billing Profile & Reimbursement Data policy alerts

Daniel Lavie — Billing Profile & Reimbursement Data

Sign up for Daniel Lavie — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References